top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.8220 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,305
Open 0.8220
Bid (Size) 0.7770 (5,000)
Ask (Size) 0.8610 (100)
Prev. Close 0.8220
Today's Range 0.8220 - 0.8220
52wk Range 0.6201 - 13.00
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion 
From FibroBiologics, Inc.
Via GlobeNewswire

Performance

YTD
-82.9%
-82.9%
1 Month
-5.4%
-5.4%
3 Month
-38.2%
-38.2%
6 Month
-85.2%
-85.2%
1 Year
-93.2%
-93.2%

More News

Read More
News headline image
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗
Via Benzinga
News headline image
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Compliant with All Nasdaq Listing Requirements
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
From USA News Group
Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.8220
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 08/04/26 04:00 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 31.45M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 31M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page